Skip to content
ATLAS PREP HQ
Fat Loss

Cagrilintide + Semaglutide

CagriSema-style combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 receptor agonist)

Dual amylin and GLP-1 pathway research aimed at appetite control and significant weight reduction.

Strong Human Evidence

Route

Subcutaneous.

Common format

5 mg + 5 mg

Research focus

obesity

Evidence level

Strong Human Evidence

Typical cycle

16+ weeks

Fat Loss research motifFat Loss

Cagrilintide + Semaglutide in 30 seconds

Atlas Fast Read

What it is

CagriSema-style combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 receptor agonist)

Why people care

Dual amylin and GLP-1 pathway research aimed at appetite control and significant weight reduction.

Human evidence

Strong Human Evidence — Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

Biggest misconception

Long-term cardiovascular and safety outcomes, comparative positioning versus other incretin therapies, durability, maintenance strategy, and final regulatory labeling remain important.

Bottom line

CagriSema-style therapy has strong human evidence for major metabolic/weight-loss endpoints and a rational two-pathway mechanism.

Overview

What is Cagrilintide + Semaglutide?

Cagrilintide + Semaglutide combines a long-acting amylin analogue with a long-acting GLP-1 receptor agonist. The clinical-development version is commonly known as CagriSema and is designed to combine two complementary satiety and appetite pathways.

The cagrilintide-semaglutide combination, commonly called CagriSema in clinical development, was advanced by Novo Nordisk to combine amylin and GLP-1 appetite pathways. Large late-stage trials followed encouraging early studies.

Mechanism

How it works

Combines amylin-receptor signaling from cagrilintide with GLP-1 receptor signaling from semaglutide. The two pathways converge on satiety and energy intake through partly distinct neural and gastrointestinal mechanisms.

Research areas

obesityweight managementappetite regulationtype 2 diabetes research

Evidence

What does the evidence actually say?

Strong Human Evidence

Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

The cagrilintide-semaglutide combination has been studied in large randomized human obesity and diabetes programs, with substantial weight-loss effects reported. Human evidence is strong for the studied metabolic endpoints, while long-term comparative safety and final labeling remain important.

Preclinical evidence

Preclinical rationale supports complementary amylin and GLP-1 signaling for appetite and energy balance. Human randomized trials now provide the more relevant evidence for the combination.

Knowledge gaps

Long-term cardiovascular and safety outcomes, comparative positioning versus other incretin therapies, durability, maintenance strategy, and final regulatory labeling remain important.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Clinical CagriSema programs pair cagrilintide and semaglutide with gradual weekly titration. Community reference: 0.25 mg of each weekly progressing toward 2.4 mg of each.

Frequency

Once weekly.

Timing

Same day each week.

Route

Subcutaneous.

Cycle length

16+ weeks

Reconstitution

Community research blend: 2 mL bacteriostatic water per 10 mg total blend (5 mg + 5 mg).

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C and use within 30 days.

Monitoring

Weight, waist, BP, HbA1c/fasting glucose, CMP/renal function as clinically indicated, lipids, hydration and GI tolerance; watch for pancreatitis/gallbladder symptoms.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Most common effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, reduced appetite and reflux. Clinically important risks can include dehydration/acute kidney injury, gallbladder disease and pancreatitis; rapid weight loss can contribute to lean-mass loss.

Contraindications

The combination remains in clinical development. Semaglutide's approved contraindications—personal/family MTC, MEN2 and serious hypersensitivity—remain relevant, alongside pregnancy and significant GI/pancreatic risk.

Interactions

Slower gastric emptying can change absorption/timing of oral medicines. When combined with insulin or insulin secretagogues, hypoglycemia risk can rise; dose adjustment belongs under medical supervision. Do not combine overlapping incretin therapies unless specifically studied/prescribed.

Stacks

Common stacks

CagriSema clinical combination

The entry itself is the studied combination of cagrilintide and semaglutide.

Strong randomized human evidence for studied metabolic endpoints.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

CagriSema-style therapy has strong human evidence for major metabolic/weight-loss endpoints and a rational two-pathway mechanism. Atlas would still separate the studied clinical product and titration from improvised gray-market mixing.

More in Fat Loss

Fat Loss

5-Amino-1MQ

Selective NNMT-inhibitor research focused on cellular energy balance and metabolic function.

Read guide

Fat Loss

AOD-9604

Modified growth-hormone fragment studied for lipolysis and fat-metabolism effects without targeting IGF-1.

Read guide

Fat Loss

Cagrilintide

Long-acting amylin-analog research focused on appetite regulation, satiety, and body-weight reduction.

Read guide